Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1994 Oct;70(4):739–742. doi: 10.1038/bjc.1994.387

Soluble c-erbB-2 fragment in serum correlates with disease stage and predicts for shortened survival in patients with early-stage and advanced breast cancer.

H Kandl 1, L Seymour 1, W R Bezwoda 1
PMCID: PMC2033409  PMID: 7522511

Abstract

Seventy-nine patients with advanced breast cancer were tested for the presence, in serum, of a 110 kDa soluble, c-erbB-2 fragment. Thirty-nine patients were seropositive. There was no correlation between seropositivity and menopausal status, or with oestrogen status. In addition, no correlation could be found between tissue c-erbB-2 immunostaining for the external domain of the c-erbB-2 receptor and the presence of soluble c-erbB-2 in serum. The presence of serum soluble c-erbB-2, however, had a significant impact on survival of patients with advanced disease, suggesting that this test may become a useful independent prognostic indicator.

Full text

PDF
739

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Borg A., Tandon A. K., Sigurdsson H., Clark G. M., Fernö M., Fuqua S. A., Killander D., McGuire W. L. HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res. 1990 Jul 15;50(14):4332–4337. [PubMed] [Google Scholar]
  2. Clark G. M., McGuire W. L. Follow-up study of HER-2/neu amplification in primary breast cancer. Cancer Res. 1991 Feb 1;51(3):944–948. [PubMed] [Google Scholar]
  3. Cline M. J., Battifora H., Yokota J. Proto-oncogene abnormalities in human breast cancer: correlations with anatomic features and clinical course of disease. J Clin Oncol. 1987 Jul;5(7):999–1006. doi: 10.1200/JCO.1987.5.7.999. [DOI] [PubMed] [Google Scholar]
  4. Greco N. J., Tenner T. E., Jr, Tandon N. N., Jamieson G. A. PPACK-thrombin inhibits thrombin-induced platelet aggregation and cytoplasmic acidification but does not inhibit platelet shape change. Blood. 1990 May 15;75(10):1989–1990. [PubMed] [Google Scholar]
  5. Gusterson B. A., Gelber R. D., Goldhirsch A., Price K. N., Säve-Söderborgh J., Anbazhagan R., Styles J., Rudenstam C. M., Golouh R., Reed R. Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol. 1992 Jul;10(7):1049–1056. doi: 10.1200/JCO.1992.10.7.1049. [DOI] [PubMed] [Google Scholar]
  6. Langton B. C., Crenshaw M. C., Chao L. A., Stuart S. G., Akita R. W., Jackson J. E. An antigen immunologically related to the external domain of gp185 is shed from nude mouse tumors overexpressing the c-erbB-2 (HER-2/neu) oncogene. Cancer Res. 1991 May 15;51(10):2593–2598. [PubMed] [Google Scholar]
  7. Leitzel K., Teramoto Y., Sampson E., Mauceri J., Langton B. C., Demers L., Podczaski E., Harvey H., Shambaugh S., Volas G. Elevated soluble c-erbB-2 antigen levels in the serum and effusions of a proportion of breast cancer patients. J Clin Oncol. 1992 Sep;10(9):1436–1443. doi: 10.1200/JCO.1992.10.9.1436. [DOI] [PubMed] [Google Scholar]
  8. Maguire H. C., Jr, Greene M. I. The neu (c-erbB-2) oncogene. Semin Oncol. 1989 Apr;16(2):148–155. [PubMed] [Google Scholar]
  9. Maguire H. C., Jr, Hellman M. E., Greene M. I., Yeh I. Expression of c-erbB-2 in in situ and in adjacent invasive ductal adenocarcinomas of the female breast. Pathobiology. 1992;60(3):117–121. doi: 10.1159/000163709. [DOI] [PubMed] [Google Scholar]
  10. Mori S., Mori Y., Mukaiyama T., Yamada Y., Sonobe Y., Matsushita H., Sakamoto G., Akiyama T., Ogawa M., Shiraishi M. In vitro and in vivo release of soluble erbB-2 protein from human carcinoma cells. Jpn J Cancer Res. 1990 May;81(5):489–494. doi: 10.1111/j.1349-7006.1990.tb02596.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Paterson M. C., Dietrich K. D., Danyluk J., Paterson A. H., Lees A. W., Jamil N., Hanson J., Jenkins H., Krause B. E., McBlain W. A. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer. Cancer Res. 1991 Jan 15;51(2):556–567. [PubMed] [Google Scholar]
  12. Poller D. N., Galea M., Pearson D., Bell J., Gullick W. J., Elston C. W., Blamey R. W., Ellis I. O. Nuclear and flow cytometric characteristics associated with overexpression of the c-erbB-2 oncoprotein in breast carcinoma. Breast Cancer Res Treat. 1991 Dec;20(1):3–10. doi: 10.1007/BF01833351. [DOI] [PubMed] [Google Scholar]
  13. Rubin L. A., Nelson D. L. The soluble interleukin-2 receptor: biology, function, and clinical application. Ann Intern Med. 1990 Oct 15;113(8):619–627. doi: 10.7326/0003-4819-113-8-619. [DOI] [PubMed] [Google Scholar]
  14. Schroeter C. A., De Potter C. R., Rathsmann K., Willighagen R. G., Greep J. C. c-erbB-2 positive breast tumours behave more aggressively in the first years after diagnosis. Br J Cancer. 1992 Oct;66(4):728–734. doi: 10.1038/bjc.1992.347. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Tandon A. K., Clark G. M., Chamness G. C., Ullrich A., McGuire W. L. HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol. 1989 Aug;7(8):1120–1128. doi: 10.1200/JCO.1989.7.8.1120. [DOI] [PubMed] [Google Scholar]
  16. Toikkanen S., Helin H., Isola J., Joensuu H. Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up. J Clin Oncol. 1992 Jul;10(7):1044–1048. doi: 10.1200/JCO.1992.10.7.1044. [DOI] [PubMed] [Google Scholar]
  17. Wright C., Angus B., Nicholson S., Sainsbury J. R., Cairns J., Gullick W. J., Kelly P., Harris A. L., Horne C. H. Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res. 1989 Apr 15;49(8):2087–2090. [PubMed] [Google Scholar]
  18. Xu F., Lupu R., Rodriguez G. C., Whitaker R. S., Boente M. P., Berchuck A., Yu Y., DeSombre K. A., Boyer C. M., Bast R. C., Jr Antibody-induced growth inhibition is mediated through immunochemically and functionally distinct epitopes on the extracellular domain of the c-erbB-2 (HER-2/neu) gene product p185. Int J Cancer. 1993 Feb 1;53(3):401–408. doi: 10.1002/ijc.2910530310. [DOI] [PubMed] [Google Scholar]
  19. Zhou D. J., Ahuja H., Cline M. J. Proto-oncogene abnormalities in human breast cancer: c-ERBB-2 amplification does not correlate with recurrence of disease. Oncogene. 1989 Jan;4(1):105–108. [PubMed] [Google Scholar]
  20. van de Vijver M. J., Peterse J. L., Mooi W. J., Wisman P., Lomans J., Dalesio O., Nusse R. Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med. 1988 Nov 10;319(19):1239–1245. doi: 10.1056/NEJM198811103191902. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES